news careers Our Science A number of deadly and difficult-to-treat diseases, including cancer and fibrosis, share common underlying disease biology: overgrowth of abnormal cells, which migrate and invade healthy tissues. Activation of the GAS6/AXL signaling pathway causes tumor invasion and metastasis, and high levels of GAS6 and AXL have been strongly associated with drug resistance, rapid disease progression, and lower survival. Current attempts to target this important pathway have fallen short, causing either undesirable off-target effects or limited efficacy. To circumvent these challenges, Aravive is taking the entirely novel approach of targeting the GAS6 ligand, rather than the AXL protein. Aravive’s lead product candidate batiraxcept (formerly AVB-500) is an ultra-high affinity decoy protein that captures GAS6, thereby potentially stopping the migration and invasion of tumor cells into healthy tissue. In preclinical studies, batiraxcept has been shown to suppress serum GAS6 to undetectable levels and correspondingly decrease metastatic disease. In clinical studies to date, batiraxcept has demonstrated a favorable safety profile and compelling early clinical activity in cancer patients. Batiraxcept’s impressive safety and tolerability profile suggests it could be ideal for use in combination with many anti-cancer drugs or as a maintenance therapy. Our proprietary biomarker is supporting development of batiraxcept in multiple oncology indications. AVB-500 Inhibits Metastasis And Tumor Growth Media Dr. Gail McIntyre, CEO of Aravive, Shares Insight on AVB-500 and its Potential Against ccRCC PharmaShots, April 12, 2021 Dr. Gail McIntyre, CEO of Aravive, Discusses the Urgent Need for Improved Therapeutic Approaches to Treat Patients with Ovarian Cancer Health Professional Radio, December 1, 2020 PharmaVOICE100, Commanders and Chiefs | Dr. Gail McIntyre, Delivering Results PharmaVOICE100, August 2020 Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials STAT First Opinion, September 4, 2019 Cell Wars – Dr. Gail McIntyre, Chief Scientific Officer, Aravive – Researching Ways to Combat Disease at the Cellular Level Finding Genius Podcast, June 27, 2019 White Paper Novel Approaches Designed to Enhance the Efficacy of Cancer Treatments by Suppressing Mechanisms of Tumor Metastasis and Chemoresistance Gail McIntyre, Ph.D. Publications A Phase 1b Study of AVB-S6-500 in Combination with Cabozantinib In Patients with Advanced Clear Cell Renal Cell Carcinoma Who Received Front-Line Treatment K. Beckermann, N. Vogelzang, S. Mao, M. Ornstein, N. Shah, H. Hammers, X. Gao, D. McDermott, E. Pennella, H. Yan, V. Esquibel, R. Rangwala, M. Campbell Society for Immunotherapy of Cancer, November 12, 2021 Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer Katherine C. Fuh, MD, PhD, Michael A. Bookman, MD, Joyce F. Liu, MD, Robert L. Coleman, MD, Thomas J. Herzog, MD, Premal H. Thaker, MD, Bradley J. Monk, MD, Randy Anderson, PhD, Gail McIntyre, PhD, DABT, Reshma Rangwala, MD, PhD, Kathleen N. Moore, MD Gynecologic Oncology, August 30, 2021 SGO 2021: Phase 1B Study of GAS6/AXL Inhibitor (AVB-500) in Recurrent, Platinum-resistant Ovarian Carcinoma Katherine C. Fuh, MD, PhD, Michael A. Bookman, MD, Robert L. Coleman, MD, Thomas J. Herzog MD, Premal H. Thaker, MD, Joyce F. Liu MD, Michelle W. Lane, PhD, Reshma A. Rangwala, MD, PhD, Gail F. McIntyre, PhD, Bradley J. Monk, MD, Kathleen N. Moore, MD Webcast: SGO 2020: AVB-S6-500, a receptor tyrosine kinase AXL inhibitor, has improved therapeutic efficacy in combination with bevacizumab in uterine serous cancer mouse model Presentation by Michael D. Toboni, MD, MPH, PGY-5 Gynecologic Oncology Fellow, Washington University, St. Louis, Dr. Katherine Fuh Lab Improving response to chemotherapy in HGSOC by inhibiting the GAS6/AXL pathway & inducing a homologous recombination (HR) deficiency Mary M Mullen, MD, Elena Lomonosova, PhD, Michael Toboni, MD, MPH, Hollie Noia, BS, Daniel Wilke, BS, Alyssa Oplt, BS, Lei Guo, MS, Lindsay M Kuroki MD, Andrea R Hagemann, MD, MSCI, Carolyn K McCourt, MD, Premal H Thaker, MD, MS, David G. Mutch, MD, Matthew A Powell, MD, Katherine C Fuh MD, PhD Siteman Cancer Center, 28 March 2020. Improving response to olaparib in uterine serous cancer through treatment with AVB-S6-500, a receptor tyrosine kinase AXL inhibitor M.D. Toboni, M.M. Mullen, J.I. Tankou, H. Noia, A. Oplt, D. Wilke, P. Cannon, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell and K.C. Fuh. Siteman Cancer Center, 4 March 2020. Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500 Laura Bonifacio, Michael Dodds, David Prohaska, Aaron Moss, Amato Giaccia, Ray Tabibiazar and Gail McIntyre. Clinical and Translational Science, 10 October 2019. doi: 10.1111/cts.12706 ESMO 2019: Phase 1b/2 Study of AVB-500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer (NCT03639246) Abstract 6602 Authors: B. Monk, R. Coleman, K. Moore, K. Fuh, L. Bonifacio, G. McIntyre, D. Prohaska, A. Giaccia, M.J. Baker, R. Tabibiazar, M. Bookman S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma Yiren Xiao, Hongjuan Zhao, Lei Tian, Rosalie Nolley, Anh N Diep, Anne Ernst, Katherine C. Fuh, Yu Rebecca Miao, Rie von Eyben, John T. Leppert, James D. Brooks, Donna M. Peehl, Amato J. Giaccia and Erinn B. Rankin. Cancer Research, 4 October 2019. doi: 10.1158/0008-5472.CAN-19-1366 Therapeutic GAS6/AXL inhibition of tumor and stromal cells increases DNA damage and improves response to chemotherapy in ovarian cancer Mary M Mullen, MD, Elena Lomonosova, PhD, Hollie Noia, BS, Lei Guo, MS, Lindsay M Kuroki MD, Andrea R Hagemann, MD, MSCI, Carolyn K McCourt, MD, Premal H Thaker, MD, MS, David G. Mutch, MD, Matthew A Powell, MD, Katherine C Fuh MD, PhD Division of Gynecologic Oncology, Washington University, St. Louis, MO Expedited Development of AVB-S6 through the use of a Proprietary Biomarker in Healthy Volunteers to Guide Dosing in Oncology Studies Gail McIntyre, Laura Bonifacio, Dave Prohaska, Jing Shang, Yoshinobu Yokota, Aaron Moss, Amato Giaccia, Michael Dodds, and Ray Tabibiazar Aravive Biologics, Inc., Houston, TX; SNBL, Everett, WA Certara L, Princeton, NJ; Stanford University, CA Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion – A New Role for the AXL Receptor Tyrosine Kinase Todd A. Aguilera and Amato J. Giaccia. DOI: 10.1158/1078-0432.CCR-17-0189 Published January 2017 Targeting GAS6 in cancer, fibrosis and viral infection Rebecca Miao, Amato Giaccia (Stanford University) and Raymond Tabibiazar (Aravive, Inc.). Drug Target Review, 9 March 2017. Issue #1, 2017. Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses Laurent Meertens, Athena Labeau, Ophelie Dejarnac, Sara Cipriani, Laura Sinigaglia, Lucie Bonnet-Madin, Tifenn Le Charpentier, Mohamed Lamine Hafirassou, Alessia Zamborlini, Van-Mai Cao-Lormeau, Muriel Coulpier, Dorothée Missé, Nolwenn Jouvenet, Ray Tabibiazar, Pierre Gressens, Olivier Schwartz, Ali Amara. DOI: http://dx.doi.org/10.1016/j.celrep.2016.12.045 Reprogramming the immunological microenvironment through radiation and targeting Axl Aguilera TA, Rafat M, Castellini L, Shehade H, Kariolis MS, Hui AB, Stehr H, von Eyben R, Jiang D, Ellies LG, Koong AC, Diehn M, Rankin EB, Graves EE, Giaccia AJ. Nat Commun. 2016 Dec 23;7:13898. doi: 10.1038/ncomms13898. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones DS 2nd, Kapur S, Mathews II, Koong AC, Rankin EB, Cochran JR, Giaccia AJ. J Clin Invest. 2016 Nov 28. [Epub ahead of print] PMID: 27893463 The Receptor Tyrosine Kinase AXL in Cancer Progression Rankin EB, Giaccia AJ. Cancers (Basel). 2016 Nov 9;8(11). PMID: 27834845 Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Oncogene. 2016 May;35(21):2687-97. PMID: 26364599 An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis Kariolis MS, Miao YR, Jones DS 2nd, Kapur S, Mathews II, Giaccia AJ, Cochran JR. Nat Chem Biol. 2014 Nov;10(11):977-83. PMID: 25242553 Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, Axelson H, Miao YR, Krieg AJ, Giaccia AJ. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13373-8. PMID: 25187556 AXL is an essential factor and therapeutic target for metastatic ovarian cancer Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ. Cancer Res. 2010 Oct 1;70(19):7570-9. PMID: 20858715 ©2021 Aravive Terms of Use | Privacy Policy